# Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis

> **NCT02391961** · PHASE2 · COMPLETED · sponsor: **VA Office of Research and Development** · enrollment: 23 (actual)

## Conditions studied

- Multiple Sclerosis
- Internuclear Ophthalmoplegia
- Fatigue

## Interventions

- **DRUG:** Dalfampridine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02391961
- **Lead sponsor:** VA Office of Research and Development
- **Sponsor class:** FED
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-01
- **Primary completion:** 2019-01-31
- **Final completion:** 2019-03-31
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2020-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02391961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02391961, "Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02391961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*